Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) - Full Text View

Purpose

To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.

Condition	Intervention	Phase
COPD COPD Exacerbation Lung Diseases Respiratory Disorders Pulmonary Disease Chronic Obstructive Lung Diseases Chronic Obstructive Airway Disease	Drug: Roflumilast Drug: Placebo	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

Resource links provided by NLM:

MedlinePlus related topics: COPD

Drug Information available for: Roflumilast

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year. [ Time Frame: Baseline to Week 52 ]
Rate of moderate or severe COPD exacerbations, defined as requiring oral or parenteral glucocorticosteroids (moderate) or requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.

Secondary Outcome Measures:

Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations) [ Time Frame: Week 0 (Visit 2) to Week 52 ]
Rate of moderate or severe COPD exacerbations, defined as requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.
Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics [ Time Frame: Week 0 (Visit 2) to Week 52 ]
Rate of moderate or severe COPD exacerbations treated with antibiotics during the double-blind treatment period.
Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Week 0 (Visit 2) to Week 52 ]
Mean change from randomization (Visit 2) over 52 weeks of treatment in predose forced expiratory volume in 1 second (FEV1)


Enrollment:	2354
Actual Study Start Date:	September 30, 2011
Study Completion Date:	January 31, 2016
Primary Completion Date:	November 30, 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Roflumilast	Drug: Roflumilast Roflumilast 500 µg, oral administration, once per day Other Name: Daliresp
Placebo Comparator: 2 Placebo	Drug: Placebo Dose-matched placebo, oral administration, once per day.

Eligibility


Ages Eligible for Study:	40 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Male or female patients at least 40 years of age
2. History of COPD (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2010) for at least 12 months prior to Screening (Visit 1) associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). Only patients with chronic bronchitis will be included (concomitant emphysema is permitted)
3. Forced expiratory volume after 1 second (FEV1)/forced vital capacity (FVC) ratio (postbronchodilator) < 70% at Screening (Visit 1)
4. FEV1 (postbronchodilator) ≤ 50% of predicted at Screening (Visit 1)
5. At least two documented moderate or severe COPD exacerbations within 12 months prior to Screening (Visit 1)
6. Patients must be on FDC LABA/ICS treatment ≥ 3 months prior to Screening (Visit 1)
7. Former smokers (defined as smoking cessation at least 1 year ago) or current smokers (including patients who ceased smoking within the past year) both with a smoking history of at least 20 pack-years

Exclusion Criteria:

1. Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics or systemic glucocorticosteroids within 4 weeks of Screening (Visit 1) (ie, patients must be clinically stable)
2. Known alpha-1-antitrypsin deficiency
3. Current diagnosis of asthma (either controlled or uncontrolled) (Note: History of childhood asthma is not exclusionary.)
4. Body mass index (BMI) ≥ 45 kg/m2
5. Patients with a history (within 5 years) or current diagnosis of cancer other than basal or squamous cell skin cancer

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01443845

Show 338 Study Locations

Sponsors and Collaborators

AstraZeneca

More Information

Additional Information:

RESPOND Protocol_Redacted This link exits the ClinicalTrials.gov site


Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT01443845 History of Changes
Other Study ID Numbers:	ROF-MD-07
Study First Received:	September 28, 2011
Results First Received:	November 30, 2016
Last Updated:	March 16, 2017

Keywords provided by AstraZeneca:


COPD Exacerbations Roflumilast Daliresp

Additional relevant MeSH terms:


Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Respiration Disorders Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 21, 2017